Q-omics provides the consensus-scored SS18L1 profile across patient tissues and cancer cell-line models. SS18L1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SS18L1 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, SS18L1 RNA expression shows 21,197 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, COAD, and ACC as cancer lineages where SS18L1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SS18L1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SS18L1 survival associations across molecular data types. SS18L1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SS18L1 RNA expression–survival associations across cancer types. High SS18L1 expression shows unfavorable associations in MESO, ACC, UVM and KICH, but favorable associations in HNSC and UCEC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SS18L1 RNA expression.
This table summarizes SS18L1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SS18L1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SS18L1 shows lower tumor expression in KIRC and higher tumor expression in COAD, BLCA, HNSC, STAD and UCEC. The COAD box plot shows higher SS18L1 RNA expression in tumor versus normal tissue (log2 FC = +0.994, t-test p < 0.001).
This table shows molecular features associated with SS18L1 in patient tissues and cancer cell lines. In patient samples, SS18L1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SS18L1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
